Sanofi/Regeneron’s Aflibercept Misses Mark In Phase II Ovarian Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Four Phase III studies underway in colorectal, pancreatic, prostate and lung cancer.
You may also be interested in...
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews.
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews.
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews